Ciprofloxacin ophthalmic solution versus rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis

Eur J Ophthalmol. 1995 Apr-Jun;5(2):82-7. doi: 10.1177/112067219500500203.

Abstract

The efficacy and safety of ciprofloxacin (0.3%) ophthalmic solution and rifamycin (1%) ophthalmic solution for the treatment of bacterial conjunctivitis and blepharitis was compared in this randomized, double-masked, parallel-group study. Forty-one patients, 19 on ciprofloxacin and 22 on rifamycin, were culture-positive on admission and evaluated for efficacy. There was clinical improvement in more than 90% of patients in each group at the end of the seven-day treatment period. However, clinical cure rates on day 7 appeared to be higher with ciprofloxacin (53%) than rifamycin (23%; p = 0.061, Mann-Whitney test). Bacteriological eradication rates were comparable: the infecting organisms were eradicated in 68% of patients on ciprofloxacin and 77% with rifamycin. There were no serious adverse reactions to either treatment. One patient in each group was withdrawn on account of a mild allergy. In conclusion, topical ciprofloxacin was effective and well tolerated and would be a particularly useful agent for the treatment of bacterial conjunctivitis and blepharitis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Administration, Topical
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bacteria / drug effects
  • Bacteria / isolation & purification
  • Blepharitis / drug therapy*
  • Blepharitis / microbiology
  • Child
  • Chronic Disease
  • Ciprofloxacin / adverse effects
  • Ciprofloxacin / therapeutic use*
  • Conjunctiva / microbiology
  • Conjunctivitis, Bacterial / drug therapy*
  • Conjunctivitis, Bacterial / microbiology
  • Double-Blind Method
  • Drug Tolerance
  • Eye Infections, Bacterial / drug therapy*
  • Eyelids / microbiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Rifamycins / adverse effects
  • Rifamycins / therapeutic use*
  • Treatment Outcome

Substances

  • Ophthalmic Solutions
  • Rifamycins
  • Ciprofloxacin